Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05023655 · ClinicalTrials.gov registry record · Phase 2
Phase II Study of Tazemetostat in Solid Tumors Harboring an ARID1A Mutation
A Phase 2 study, sponsored by Prisma Health-Upstate.
- Terminated
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
NCT05023655 is a Phase 2 study that was terminated before completion, run by Prisma Health-Upstate. The registered enrollment target is 20 participants.
The verdict
NCT05023655, a Phase 2 study, was terminated before completion, sponsored by Prisma Health-Upstate.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
Study Summary
The FDA approved targeted agent tazemetostat inhibits EZH2 and induces durable tumor responses in patients with B-cell non-Hodgkin's lymphoma and epithelioid sarcomas. Responses have also been demonstrated in INI1 and SMARCA4 negative solid tumors patients. Since EZH2 plays a critical role in driving the biology of ARID1A mutated malignancies, we hypothesize that inhibition of EZH2 with tazemetostat will lead to significant clinical benefit in ARID1A mutated malignancies.
Interventions
- DRUG Tazemetostat
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2022-01-06 |
| Est. Completion | 2026-03-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05023655
The ClinicalTrials.gov registry entry for NCT05023655 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Prisma Health-Upstate, which has 67 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Tazemetostat is the first listed.
NCT05023655 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05023655 about?
NCT05023655 is a clinical study titled "Phase II Study of Tazemetostat in Solid Tumors Harboring an ARID1A Mutation". The FDA approved targeted agent tazemetostat inhibits EZH2 and induces durable tumor responses in patients with B-cell non-Hodgkin's lymphoma and epithelioid sarcomas. Responses have also been demonstrated in INI1 and SMARCA4 negative solid tumors patients. Since EZH2 plays a critical role in drivin...
What is the current status of trial NCT05023655?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2022-01-06. Estimated completion is 2026-03-06.
What interventions are being tested in trial NCT05023655?
The interventions under investigation include: Tazemetostat (DRUG).
Who is sponsoring clinical trial NCT05023655?
This trial is sponsored by Prisma Health-Upstate, which has 67 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.